Citations

Showing 10 of 108119 citations.

The Development of a Novel Lightweight Transradial Prosthetic: A Proof-of-Concept Study
McBryan, Sarah , Belle, Jeffrey T. La , Malkoc, Aldin

Mayo Clinic

Technology and Innovation | January 14, 2019 | Volume: 20 | Issue: 1-2 | Pages: 47-53

10.21300/20.1-2.2018.47 Get It

Brain MR Radiomics to Differentiate Cognitive Disorders
Ranjbar, Sara , Velgos, Stefanie N., Dueck, Amylou C. , Geda, Yonas E. , Mitchell, J. Ross , Initiative, The Alzheimer's Disease Neuroimaging, Dueck, A. C. , Geda, Yonas E , Initiative, The Alzheimer's Disease Neuroimaging

Mayo Clinic

The Journal of Neuropsychiatry and Clinical Neurosciences | January 14, 2019 | Volume: 31 | Issue: 3 | Pages: 210-219

10.1176/appi.neuropsych.17120366 | PMID 30636564 Get It

The Effect on Heart Rate of Neuromuscular Blockade Reversal by Pyridostigmine
Long, Geoffrey J., Marsh, Herbert W.

Mayo Clinic

Anaesthesia and Intensive Care | January 14, 2019 | Volume: 9 | Issue: 2 | Pages: 144-146

10.1177/0310057x8100900208 | PMID 7258611 Get It

Pyridostigmine without atropine, pyridostigmine with atropine or neostigmine with atropine were used to antagonise neuro-muscular blockade induced by d-tubocurarine in forty otherwise healthy, female patients recovering from gynaecological surgery. Pulse rates fell significantly (P < 0.01 control heart rate 72 ± 18 beats/min (M ± SD) to 55 ± 13 beats/min) at ten minutes after pyridostigmine (10 mg/70 kg), necessitating administration of atropine (1.25 mg/70 kg) by fifteen minutes after pyridostigmine. After an initial rise in rate, pulse rates also fell significantly (P < 0 01 control heart rate 70 ± 12 beats/min to 44 ± 11 beats/min) at fifteen minutes after injection of neostigmine (2.5 mg/70 kg) with atropine (1.25 mg/70 kg) By contrast when pyrdostigmine and atropine were used together, pulse rates rose and then fell, but mean values never fell below control during a twenty-minute observation period. It was concluded that pyridostigmine should not be given alone, but requires the use of atropine to prevent bradycardia. This combination may, however, provide a more stable heart rate than that seen with neostigmine and atropine in usual doses, when these drugs are used to antagonise d-tubocurarine.
Relationship between Selective Serotonin Reuptake Inhibitors and Risk of Dental Implant Failure
Gonzalez, Ricardo L. Vidal, Lohse, Christine M. , Carr, Alan B. , Jia, Li

Mayo Clinic

Journal of Prosthodontics | January 14, 2019 | Volume: 28 | Issue: 3 | Pages: 252-257

10.1111/jopr.13015 | PMID 30637850 Get It

AbstractPurposeTo identify associations between implant failure and selective serotonin reuptake inhibitor (SSRI) medication use in a cohort of consecutive patients receiving dental implants during a 20‐year period.Materials and MethodsA retrospective review was conducted of all patients who received at least 1 dental implant from January 1, 1995, through December 31, 2014, assessing their history of SSRI use, active SSRI use, and SSRI use during follow‐up with implant failure. Cox proportional hazards regression models assessed associations between demographic characteristics and SSRI use with implant failure, and outcomes were summarized with hazard ratios (HRs) and 95% confidence intervals (CIs). Follow‐up SSRI use was analyzed with time‐dependent covariates.ResultsDuring the study period, 5456 patients received their first implant (median age, 53 years). The median duration of follow‐up was 5.3 years (interquartile range, 2.3‐10.2 years) for the 4927 patients who did not have implant failure. For the 529 patients who had implant failure, it occurred at a median of 0.5 years. After adjusting for age, sex, and era of implant, history of use of the SSRI sertraline was associated with an increased risk of implant failure among all patients (hazard ratio [HR], 1.60; 95% CI, 1.15‐2.23; p = 0.006) and among the subset of patients with a history of SSRI use (HR, 1.64; 95% CI, 1.07‐2.52; p = 0.02).ConclusionsIn the population reviewed, a history of sertraline use was associated with a 60% greater risk of implant failure; however, active SSRI use at the time of implant placement or during follow‐up was not significantly associated with an increased risk of implant failure.
Calculator‐free point‐of‐care prognostication in myelodysplastic syndromes
Tefferi, Ayalew , Hanson, Curtis A. , Pardanani, Animesh , Gangat, Naseema , Gangat, Naseema , Ketterling, Rhett P.

Mayo Clinic

American Journal of Hematology | January 14, 2019 | Volume: 94 | Issue: 4 | Pages: No page available

10.1002/ajh.25400 | PMID 30637785 Get It

The cancer‐related transcription factor RUNX2 modulates expression and secretion of the matricellular protein osteopontin in osteosarcoma cells to promote adhesion to endothelial pulmonary cells and lung metastasis
Villanueva, Francisco , Briceño, Pedro, Varela, Nelson , Stevenson, A.E., Jerez, Sofía , Tempio, Fabián , Chnaiderman, Jonás , Perez, Carola, Villarroel, Milena , Concha, Emma , Khani, Farzaneh , Thaler, Roman , Salazar‐Onfray, Flavio , Wijnen, André J. van , Galindo, Mario , van Wijnen, Andre J , Galindo, Mario A , Araya, Hector, Stein, Gary S.

Mayo Clinic

Journal of Cellular Physiology | January 14, 2019 | Volume: 234 | Issue: 8 | Pages: 13659-13679

10.1002/jcp.28046 | PMID 30637720 Get It

Abstract Osteosarcomas are bone tumors that frequently metastasize to the lung. Aberrant expression of the transcription factor, runt‐related transcription factor 2 (RUNX2), is a key pathological feature in osteosarcoma and associated with loss of p53 and miR‐34 expression. Elevated RUNX2 may transcriptionally activate genes mediating tumor progression and metastasis, including the RUNX2 target gene osteopontin ( OPN/SPP1 ). This gene encodes a secreted matricellular protein produced by osteoblasts to regulate bone matrix remodeling and tissue calcification. Here we investigated whether and how the RUNX2/OPN axis regulates lung metastasis of osteosarcoma. Importantly, RUNX2 depletion attenuates lung metastasis of osteosarcoma cells in vivo. Using next‐generation RNA‐sequencing, protein‐based assays, as well as the loss‐ and gain‐of‐function approaches in selected osteosarcoma cell lines, we show that osteopontin messenger RNA levels closely correlate with RUNX2 expression and that RUNX2 controls the levels of secreted osteopontin. Elevated osteopontin levels promote heterotypic cell–cell adhesion of osteosarcoma cells to human pulmonary microvascular endothelial cells, but not in the presence of neutralizing antibodies. Collectively, these findings indicate that the RUNX2/OPN axis regulates the ability of osteosarcoma cells to attach to pulmonary endothelial cells as a key step in metastasis of osteosarcoma cells to the lung.
Paraben Toxicology
Fransway, Anthony F., Fransway, Paulina J., Belsito, D. , Yiannias, James A.

Mayo Clinic

Dermatitis® | January 13, 2019 | Volume: 30 | Issue: 1 | Pages: 32-45

10.1097/der.0000000000000428 | PMID 30570577 Get It

Parabens now being formally declared as the American Contact Dermatitis Society (non)allergen of the year, the allergologic concerns regarding parabens raised during the past century are no longer a significant issue. The more recent toxicological concerns regarding parabens are more imposing, stemming from the gravity of the noncutaneous adverse health effects for which they have been scrutinized for the past 20 years. These include endocrine activity, carcinogenesis, infertility, spermatogenesis, adipogenesis, perinatal exposure impact, and nonallergologic cutaneous, psychologic, and ecologic effects. To assert that parabens are safe for use as currently used in the cosmetics, food, and pharmaceutical industries, all toxicological end points must be addressed. We seek to achieve perspective through this exercise: perspective for the professional assessing systemic risk of parabens by all routes of exposure. The data reviewed in this article strive to provide a balanced perspective for the consumer hopefully to allay concerns regarding the safety of parabens and facilitate an informed decision-making process. Based on currently available scientific information, claims that parabens are involved in the genesis or propagation of these controversial and important health problems are premature. Haste to remove parabens from consumer products could result in their substitution with alternative, less proven, and potentially unsafe alternatives, especially given the compelling data supporting the lack of significant dermal toxicity of this important group of preservatives.
Elevated Sera sST2 Is Associated With Heart Failure in Men ≤50 Years Old With Myocarditis
Coronado, Michael J., Bruno, Katelyn A. , Blauwet, Lori A., Tschöpe, Carsten , Cunningham, Madeleine W. , Pankuweit, Sabine , Linthout, Sophie Van , Jeon, Eun‐Seok, McNamara, Dennis M. , Krejčí, Jan , Douglass, Erika J. , Abston, Eric , Bucek, Adriana, Frisancho, J. Augusto, Greenaway, Merci S., Hill, Anneliese R., Schultheiß, Heinz‐Peter , Cooper, Leslie T. , Fairweather, DeLisa , Fairweather, DeLisa , Cooper, Leslie T , Tschöpe, Carsten , Bruno, Katelyn A , Jeon, Eun‐Seok , Vašků, Julie Bienertová

Mayo Clinic

Journal of the American Heart Association | January 13, 2019 | Volume: 8 | Issue: 2 | Pages: No page available

10.1161/jaha.118.008968 | PMID 30638108 Get It

Background Myocarditis is an important cause of acute and chronic heart failure. Men with myocarditis have worse recovery and an increased need for transplantation compared with women, but the reason for the sex difference remains unclear. Elevated sera soluble (s) ST 2 predicts mortality from acute and chronic heart failure, but has not been studied in myocarditis patients. Methods and Results Adults with a diagnosis of clinically suspected myocarditis (n=303, 78% male) were identified according to the 2013 European Society of Cardiology position statement. Sera sST 2 levels were examined by ELISA in humans and mice and correlated with heart function according to sex and age. Sera sST 2 levels were higher in healthy men ( P =8×10 −6 ) and men with myocarditis ( P =0.004) compared with women. sST 2 levels were elevated in patients with myocarditis and New York Heart Association class III ‐ IV heart failure ( P =0.002), predominantly in men ( P =0.0003). Sera sST 2 levels were associated with New York Heart Association class in men with myocarditis who were ≤50 years old ( r =0.231, P =0.0006), but not in women ( r =0.172, P =0.57). Sera sST 2 levels were also significantly higher in male mice with myocarditis ( P =0.005) where levels were associated with cardiac inflammation. Gonadectomy with hormone replacement showed that testosterone ( P <0.001), but not estradiol ( P =0.32), increased sera sST 2 levels in male mice with myocarditis. Conclusions We show in a well‐characterized subset of heart failure patients with clinically suspected and biopsy‐confirmed myocarditis that elevated sera sST 2 is associated with an increased risk of heart failure based on New York Heart Association class in men ≤50 years old.
Procedural predictors of epidural blood patch efficacy in spontaneous intracranial hypotension
Pagani-Estévez, Gabriel L., Cutsforth‐Gregory, Jeremy K. , Mokri, Bahram, Piepgras, David G., Mauck, William D. , Eldrige, Jason S. , Watson, James C. , Morris, Jonathan M.

Mayo Clinic

Regional Anesthesia & Pain Medicine | January 13, 2019 | Volume: 44 | Issue: 2 | Pages: 212-220

10.1136/rapm-2018-000021 | PMID 30636714 Get It

Background and objective Epidural blood patch (EBP) is a safe and effective treatment for spontaneous intracranial hypotension (SIH), but clinical and procedural variables that predict EBP efficacy remain nebulous. Methods This study is an institutional review board-approved retrospective case series with dichotomized EBP efficacy defined at 3 months. The study included 202 patients receiving 604 EBPs; iatrogenic cerebrospinal fluid leaks were excluded. Results Of the EBPs, 473 (78%) were single-level, 349 (58%) lumbar, 75 (12%) bilevel, and 56 (9%) multilevel (≥3 levels). Higher volume (OR 1.64; p<0.0001), bilevel (3.17, 1.91–5.27; p<0.0001), and multilevel (117.3, 28.04–490.67; p<0.0001) EBP strategies predicted greater efficacy. Only volume (1.64, 1.47–1.87; p<0.0001) remained significant in multivariate analysis. Site-directed patches were more effective than non-targeted patches (8.35, 0.97–72.1; p=0.033). Lower thoracic plus lumbar was the most successful bilevel strategy, lasting for a median of 74 (3–187) days. Conclusions In this large cohort of EBP in SIH, volume, number of spinal levels injected, and site-directed strategies significantly correlated with greater likelihood of first EBP efficacy. Volume and leak site coverage likely explain the increased efficacy with bilevel and multilevel patches. In patients with cryptogenic leak site, and either moderate disability, negative prognostic brain MRI findings for successful EBP, or failed previous lumbar EBP, a low thoracic plus lumbar bilevel EBP strategy is recommended. Multilevel EBP incorporating transforaminal administration and fibrin glue should be considered in patients refractory to bilevel EBP. An algorithmic approach to treating SIH is proposed.
Association of Obstructive Sleep Apnea With Cardiovascular Outcomes in Patients With Acute Coronary Syndrome
Fan, Jingyao , Ma, Xinliang , Wei, Yongxiang , Wang, Xiao, Somers, Virend K. , Nie, Shaoping

Mayo Clinic

Journal of the American Heart Association | January 12, 2019 | Volume: 8 | Issue: 2 | Pages: No page available

10.1161/jaha.118.010826 | PMID 30636505 Get It

Background The prognostic significance of obstructive sleep apnea ( OSA ) in patients with acute coronary syndrome ( ACS ) in the contemporary era is unclear. We performed a large, prospective cohort study and did a landmark analysis to delineate the association of OSA with subsequent cardiovascular events after ACS onset. Methods and Results Between June 2015 and May 2017, consecutive eligible patients admitted for ACS underwent cardiorespiratory polygraphy during hospitalization. OSA was defined as an apnea‐hypopnea index ≥15 events·h −1 . The primary end point was major adverse cardiovascular and cerebrovascular event ( MACCE ), including cardiovascular death, myocardial infarction, stroke, ischemia‐driven revascularization, or hospitalization for unstable angina or heart failure. OSA was present in 403 of 804 (50.1%) patients. During median follow‐up of 1 year, cumulative incidence of MACCE was significantly higher in the OSA group than in the non‐ OSA group (log‐rank, P =0.041). Multivariate analysis showed that OSA was nominally associated with incidence of MACCE (adjusted hazard ratio, 1.55; 95% CI, 0.94–2.57; P =0.085). In the landmark analysis, patients with OSA had 3.9 times the risk of incurring a MACCE after 1 year (adjusted hazard ratio, 3.87; 95% CI, 1.20–12.46; P =0.023), but no increased risk was found within 1‐year follow‐up (adjusted hazard ratio, 1.18; 95% CI, 0.67–2.09; P =0.575). No significant differences were found in the incidence of cardiovascular death, myocardial infarction, and ischemia‐driven revascularization, except for a higher rate of hospitalization for unstable angina in the OSA group than in the non‐ OSA group (adjusted hazard ratio, 2.10; 95% CI, 1.09–4.05; P =0.027). Conclusions There was no independent correlation between OSA and 1‐year MACCE after ACS . The increased risk associated with OSA was only observed after 1‐year follow‐up. Efficacy of OSA treatment as secondary prevention after ACS requires further investigation.